Vitura Health Past Earnings Performance
Past criteria checks 3/6
Vitura Health has been growing earnings at an average annual rate of 74%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 63% per year. Vitura Health's return on equity is 23.6%, and it has net margins of 7.9%.
Key information
74.0%
Earnings growth rate
106.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 63.0% |
| Return on equity | 23.6% |
| Net Margin | 7.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25
Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Feb 25Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)
Dec 13Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet
Nov 21Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?
Nov 01Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Jul 18Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%
Sep 12If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity
Sep 05Revenue & Expenses BreakdownBeta
How Vitura Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 120 | 9 | 25 | 0 |
| 30 Sep 23 | 119 | 12 | 23 | 0 |
| 30 Jun 23 | 117 | 14 | 21 | 0 |
| 31 Mar 23 | 107 | 12 | 20 | 0 |
| 31 Dec 22 | 97 | 10 | 19 | 0 |
| 30 Sep 22 | 82 | 8 | 17 | 0 |
| 30 Jun 22 | 67 | 6 | 16 | 0 |
| 31 Mar 22 | 54 | 5 | 12 | 0 |
| 31 Dec 21 | 42 | 5 | 8 | 0 |
| 30 Sep 21 | 32 | 3 | 6 | 0 |
| 30 Jun 21 | 22 | 1 | 5 | 0 |
| 31 Mar 21 | 15 | 0 | 5 | 0 |
| 31 Dec 20 | 7 | -2 | 5 | 0 |
| 30 Sep 20 | 4 | -3 | 5 | 0 |
| 30 Jun 20 | 0 | -4 | 4 | 0 |
| 31 Mar 20 | 0 | -4 | 4 | 0 |
| 31 Dec 19 | 0 | -4 | 3 | 0 |
| 30 Sep 19 | 0 | -3 | 3 | 0 |
| 30 Jun 19 | 0 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
Quality Earnings: VIT has high quality earnings.
Growing Profit Margin: VIT's current net profit margins (7.9%) are lower than last year (10.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIT has become profitable over the past 5 years, growing earnings by 74% per year.
Accelerating Growth: VIT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VIT had negative earnings growth (-9.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16%).
Return on Equity
High ROE: VIT's Return on Equity (23.6%) is considered high.